Impaired NLRP3 inflammasome activation by chitin underlies refractory chromoblastomycosis caused by Fonsecaea pedrosoi muriform cells - Report - MDSpire

Impaired NLRP3 inflammasome activation by chitin underlies refractory chromoblastomycosis caused by Fonsecaea pedrosoi muriform cells

  • By

  • Yao Chen

  • Zilu Qu

  • Zhaolan Xie

  • Xiaowen Wang

  • Zhongsheng Tong

  • Luoyao Yang

  • Xu Zhang

  • Liuqing Chen

  • Bilin Dong

  • July 14, 2026

Share

Clinical Report: Chitin-Induced Impairment of NLRP3 Inflammasome Activation

Overview

This study investigates the role of chitin accumulation on muriform cells in modulating NLRP3 activation. Findings indicate that while NLRP3 mediates host defense, its activation is impaired by chitin.

Background

Chromoblastomycosis (CBM) is a chronic fungal infection primarily caused by Fonsecaea pedrosoi, characterized by muriform cells that evade immune clearance. Understanding the mechanisms behind the chronicity of CBM is crucial, especially given the inadequate efficacy of current antifungal therapies. The role of the NLRP3 inflammasome in antifungal immunity and its modulation by chitin is a significant area of research.

Data Highlights

ParameterDay 7Day 90
IL-1βHighDeclined
IL-17AHighDeclined
MPO+ NeutrophilsAbundantSurrounded by Macrophages
Muriform CellsPresentPersisted

Key Findings

  • Chitin accumulation on muriform cells suppresses NLRP3 activation.
  • Human lesions show high levels of IL-1β, IL-6, TNF-α, and IL-10 compared to normal skin.
  • In WT mice, lesions transition from purulent to granulomatous over time.
  • NLRP3–/– mice produced IL-1β and IL-17A independently of NLRP3.
  • Chitinase-treated muriform cells induced higher NLRP3-dependent cytokine production in BMDMs.

Clinical Implications

Understanding the dynamics of NLRP3 activation could inform future therapeutic approaches.

Conclusion

Chitin accumulation impairs NLRP3 inflammasome activation, contributing to the chronicity of chromoblastomycosis despite the presence of an immune response.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. Clinical Overview of Chromoblastomycosis | Chromoblastomycosis | CDC
  6. Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies - PubMed
  7. The Major Chromoblastomycosis Etiologic Agent Fonsecaea pedrosoi Activates the NLRP3 Inflammasome
  8. Clinical Overview of Chromoblastomycosis | Chromoblastomycosis | CDC
  9. Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies - PubMed
  10. The Major Chromoblastomycosis Etiologic Agent Fonsecaea pedrosoi Activates the NLRP3 Inflammasome

Original Source(s)

Related Content